British drugmaker confirmed review on Sunday
British drugmaker confirmed review on Sunday
Partnership aims to advance disease severity testing programme for COVID-19
Gilead and Galapagos’ application for oral JAK1 inhibitor validated by agency
Data presented at virtual European Academy of Dermatology and Venereology congress
Obesity management treatment recommended following confidential discount
It is hoped that findings from the NIHR-funded trial will help better inform treatment decisions
The move gives the French drug giant access to Kiadis’ natural killer cell technology platform
The oral, once-daily therapy is designed to prevent attacks and reduce burden of therapy
Zejula is the first PARP inhibitor to be approved as monotherapy in the EU for patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status
Findings come from new research funded by Cancer Research UK and NIHR
Drug significantly eliminated oral corticosteroid (OCS) in OCS-dependent asthma patients
The UK BIA Antibody Taskforce is set to take combinations into further development as a cocktail
Collaboration includes two therapeutic candidates – MP0420 and MP0423
Agreement will also see companies develop treatments for frontotemporal dementia
New guidance based on research from University of Manchester